Gemin X Pharmaceuticals to Present Mechanism-of-Action of Novel Anti-Cancer
Compound at the 15th International Molecular Medicine Tri-Conference
- Case Study to Discuss NAMPRT Inhibitor GMX1777-
Malvern, PA and Montréal, Canada - March 20, 2008 -Gemin X Pharmaceuticals today announced that Dr. Anne Roulston will present at the Cambridge Healthtech Institute's Molecular Medicine Tri-Conference on March 27, 2008 at 9:30 AM PDT at the Moscone Centre in San Francisco. Dr. Roulston will discuss the approach used to identify the key mechanism of action of GMX1778 and the new opportunities this information provides for the clinical development of GMX1777.
GMX1777 is a soluble prodrug of the pharmacologically active compound GMX1778. Gemin X discovered that GMX1778 functions by inhibiting nicotinamide phosphoribosyl transferase (NAMPRT), an enzyme that is a recognized anti-cancer target and is up-regulated in many cancers. GMX1778 limits the production of NAD+, abrogating the dependence of cancer cells on high energy metabolism and certain DNA repair pathways. Data derived from in vitro and in vivo studies suggest that GMX1777 exhibits potent mechanism-based efficacy against a wide range of human tumors. The compound is currently in a Phase I open-label, dose-escalation clinical trial in patients with refractory solid tumors and lymphomas.
About Gemin X Pharmaceuticals
Gemin X Pharmaceuticals specializes in the discovery and development of novel target-based cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase II clinical trials. Gemin X's second compound GMX1777, is a potent, small molecule that specifically inhibits nicotinamide phosphoribosyl transferase (NAMPRT), resulting in cancer cell death independently of the tumor suppressor p53. It is currently in a Phase I clinical trial in patients with refractory solid tumors and lymphomas. Gemin X is privately held and is located in Malvern, Pennsylvania and Montreal, Canada.
return to top
